

[Home](#) > [Latest news](#) > [2019.01.14 - Strontium ranelate returns to the UK as an osteoporosis drug treatment](#)

# 2019.01.14 - Strontium ranelate returns to the UK as an osteoporosis drug treatment

## Strontium ranelate returns to the UK as an osteoporosis drug treatment

Expertise

04 Jan 2019

People with osteoporosis in the UK now have access to the osteoporosis medication strontium ranelate, which returned to the UK market today.

The drug was previously available under the brand Protelos but was [pulled from the UK market in August 2017](#).

Servier, who manufactured the drug at the time, said the decision to cease marketing and supply was based on commercial reasons. This followed safety concerns about the drug being connected to cardiovascular risks, which had led to its limited use and a continuous decline in the number of people being treated with it.

Pharmaceutical company Aristo has now taken on the manufacturing of strontium ranelate, which is available for prescription for the treatment of severe osteoporosis in postmenopausal women and adult men who are at high risk of fracture.

"I'm pleased that strontium ranelate is available as a drug treatment again," said Dr Nicola Peel, clinical adviser for the National Osteoporosis Society.

"While it is not a suitable drug treatment for everyone with osteoporosis because of some of the potential side-effects, it may be the right choice for some patients – many of whom would otherwise have no other suitable treatment to reduce their risk of broken bones."

Copyright © Royal Osteoporosis Society 2020

**President:** HRH The Duchess of Cornwall

Royal Osteoporosis Society is a registered charity no. 1102712 in England and Wales, no. SC039755 in Scotland, and no. 1284 in Isle of Man. Registered as a company limited by guarantee in England and Wales no. 4995013, and foreign company no. 006188F in Isle of Man.

Registered address:

Manor Farm, Skinner's Hill, Camerton, Bath BA2 0PJ

**Formerly the National Osteoporosis Society**